An adaptable implementation package targeting evidence-based indicators in primary care: A pragmatic cluster-randomised evaluation
Autoři:
Thomas A. Willis aff001; Michelle Collinson aff002; Liz Glidewell aff003; Amanda J. Farrin aff002; Michael Holland aff002; David Meads aff001; Claire Hulme aff004; Duncan Petty aff005; Sarah Alderson aff001; Suzanne Hartley aff002; Armando Vargas-Palacios aff001; Paul Carder aff006; Stella Johnson aff006; Robbie Foy aff001;
Působiště autorů:
Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom
aff001; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
aff002; Department of Health Sciences, Hull York Medical School, University of York, York, United Kingdom
aff003; College of Medicine and Health, University of Exeter, Exeter, United Kingdom
aff004; School of Pharmacy and Medical Sciences, University of Bradford, Bradford, United Kingdom
aff005; West Yorkshire Research and Development, NHS Bradford Districts CCG, Bradford, United Kingdom
aff006
Vyšlo v časopise:
An adaptable implementation package targeting evidence-based indicators in primary care: A pragmatic cluster-randomised evaluation. PLoS Med 17(2): e32767. doi:10.1371/journal.pmed.1003045
Kategorie:
Research Article
doi:
https://doi.org/10.1371/journal.pmed.1003045
Souhrn
Background
In primary care, multiple priorities and system pressures make closing the gap between evidence and practice challenging. Most implementation studies focus on single conditions, limiting generalisability. We compared an adaptable implementation package against an implementation control and assessed effects on adherence to four different evidence-based quality indicators.
Methods and findings
We undertook two parallel, pragmatic cluster-randomised trials using balanced incomplete block designs in general practices in West Yorkshire, England. We used ‘opt-out’ recruitment, and we randomly assigned practices that did not opt out to an implementation package targeting either diabetes control or risky prescribing (Trial 1); or blood pressure (BP) control or anticoagulation in atrial fibrillation (AF) (Trial 2). Within trials, each arm acted as the implementation control comparison for the other targeted indicator. For example, practices assigned to the diabetes control package acted as the comparison for practices assigned to the risky prescribing package. The implementation package embedded behaviour change techniques within audit and feedback, educational outreach, and computerised support, with content tailored to each indicator. Respective patient-level primary endpoints at 11 months comprised the following: achievement of all recommended levels of haemoglobin A1c (HbA1c), BP, and cholesterol; risky prescribing levels; achievement of recommended BP; and anticoagulation prescribing. Between February and March 2015, we recruited 144 general practices collectively serving over 1 million patients. We stratified computer-generated randomisation by area, list size, and pre-intervention outcome achievement. In April 2015, we randomised 80 practices to Trial 1 (40 per arm) and 64 to Trial 2 (32 per arm). Practices and trial personnel were not blind to allocation. Two practices were lost to follow-up but provided some outcome data. We analysed the intention-to-treat (ITT) population, adjusted for potential confounders at patient level (sex, age) and practice level (list size, locality, pre-intervention achievement against primary outcomes, total quality scores, and levels of patient co-morbidity), and analysed cost-effectiveness. The implementation package reduced risky prescribing (odds ratio [OR] 0.82; 97.5% confidence interval [CI] 0.67–0.99, p = 0.017) with an incremental cost-effectiveness ratio of £1,359 per quality-adjusted life year (QALY), but there was insufficient evidence of effect on other primary endpoints (diabetes control OR 1.03, 97.5% CI 0.89–1.18, p = 0.693; BP control OR 1.05, 97.5% CI 0.96–1.16, p = 0.215; anticoagulation prescribing OR 0.90, 97.5% CI 0.75–1.09, p = 0.214). No statistically significant effects were observed in any secondary outcome except for reduced co-prescription of aspirin and clopidogrel without gastro-protection in patients aged 65 and over (adjusted OR 0.62; 97.5% CI 0.39–0.99; p = 0.021). Main study limitations concern our inability to make any inferences about the relative effects of individual intervention components, given the multifaceted nature of the implementation package, and that the composite endpoint for diabetes control may have been too challenging to achieve.
Conclusions
In this study, we observed that a multifaceted implementation package was clinically and cost-effective for targeting prescribing behaviours within the control of clinicians but not for more complex behaviours that also required patient engagement.
Trial registration
The study is registered with the ISRCTN registry (ISRCTN91989345).
Klíčová slova:
Atrial fibrillation – Blood pressure – Cost-effectiveness analysis – diabetes mellitus – HbA1c – Chronic kidney disease – NSAIDs – Primary care
Zdroje
1. Levine DM, Linder JA, Landon BE. The quality of outpatient care delivered to adults in the United States, 2002 to 2013. JAMA Intern Med. 2016;176(12): 1778–1790. doi: 10.1001/jamainternmed.2016.6217 27749962
2. Cooksey R. A review of UK health research funding. London: HMSO; 2006.
3. Baird B, Charles A, Honeyman M, Maguire D, Das P. Understanding pressures in general practice. London: The King’s Fund; 2016.
4. Hobbs FDR, Bankhead C, Mukhtar T, Stevens S, Perera-Salazar R, Holt T, et al. Clinical workload in UK primary care: a retrospective analysis of 100 million consultations in England, 2007–14. Lancet. 2016;387(10035): 2323–2330. doi: 10.1016/S0140-6736(16)00620-6 27059888
5. Rushforth B, Stokes T, Andrews E, Willis TA, McEachan R, Faulkner S, et al. Developing ‘high impact’ guideline-based quality indicators for UK primary care: a multi-stage consensus process. BMC Fam Pract. 2015;16(1): 156.
6. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004;8(6): iii–iv, 1–72. doi: 10.3310/hta8060 14960256
7. Willis TA, Rushforth B, West R, Faulkner S, Stokes T, Glidewell L, et al. Variations in achievement of evidence-based, high-impact quality indicators in general practice: an observational study. PLoS ONE. 2017;12(7): e0177949. doi: 10.1371/journal.pone.0177949 28704407
8. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. London: Royal College of Physicians; 2015.
9. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable admissions to hospital? A systematic review. Brit J Clin Pharmacol. 2007;63(2): 136–147.
10. The Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384(9943): 591–598. doi: 10.1016/S0140-6736(14)61212-5 25131978
11. National Institute for Health and Care Excellence. Atrial fibrillation: the management of atrial fibrillation. London: National Institute for Health and Care Excellence; 2014.
12. Ivers N, Jamtvedt G, Flottorp S, Young JM, Odgaard-Jensen J, French SD, et al. Audit and feedback: effects on professional practice and patient outcomes. Cochrane Database Syst Rev. 2012(6). Art. No.: CD000259. doi: 10.1002/14651858.CD000259.pub3 22696318
13. O’Brien MA, Rogers S, Jamtvedt G, Oxman AD, Odgaard-Jensen J, Kristoffersen DT, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2007(4). Art. No.: CD000409. doi: 10.1002/14651858.CD000409.pub2 17943742
14. Shojania KG, Jennings A, Mayhew A, Ramsay CR, Eccles MP, Grimshaw J. The effects of on-screen, point of care computer reminders on processes and outcomes of care. Cochrane Database Syst Rev. 2009(3). Art.No.: CD001096. doi: 10.1002/14651858.CD001096.pub2 19588323
15. Lawton R, Heyhoe J, Louch G, Ingleson E, Glidewell L, Willis TA, et al. Using the Theoretical Domains Framework (TDF) to understand adherence to multiple evidence-based indicators in primary care: a qualitative study. Implement Sci. 2016;11(113).
16. Glidewell L, Willis TA, Petty D, Lawton R, McEachan RRC, Ingleson E, et al. To what extent can behaviour change techniques be identified within an adaptable implementation package for primary care? A prospective directed content analysis. Implement Sci. 2018;13(32).
17. Eccles M, Grimshaw J, Campbell M, Ramsay C. Research designs for studies evaluating the effectiveness of change and improvement strategies. Qual Saf Health Care. 2003;12(1): 47–52. doi: 10.1136/qhc.12.1.47 12571345
18. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350: h2147. doi: 10.1136/bmj.h2147 25956159
19. Lord PA, Willis TA, Carder P, West RM, Foy R. Optimizing primary care research participation: a comparison of three recruitment methods in data-sharing studies. Fam Pract. 2016;33(2): 200–204. doi: 10.1093/fampra/cmw003 26921610
20. Willis TA, Hartley S, Glidewell L, Farrin AJ, Lawton R, McEachan RRC, et al. Action to Support Practices Implement Research Evidence (ASPIRE): protocol for a cluster-randomised evaluation of adaptable implementation packages targeting ‘high impact’ clinical practice recommendations in general practice. Implement Sci. 2016;11(1): 1–11.
21. Doran T, Fullwood C, Gravelle H, Reeves D, Kontopantelis E, Hiroeh U, et al. Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med. 2006;355(4): 375–384. doi: 10.1056/NEJMsa055505 16870916
22. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56(9): 1925–1933. doi: 10.1007/s00125-013-2940-y 23793713
23. Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FD, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011;378(9798): 1219–1230. doi: 10.1016/S0140-6736(11)61184-7 21868086
24. Department for Communities and Local Government. English indices of deprivation 2015 [Cited 2019 Nov 12]. https://www.gov.uk/government/statistics/english-indices-of-deprivation-2015
25. Baker R, Camosso-Stefinovic J, Gillies C, Shaw EJ, Cheater F, Flottorp S, et al. Tailored interventions to address determinants of practice. Cochrane Database Syst Rev. 2015(4). Art. No.: CD005470. doi: 10.1002/14651858.CD005470.pub3 25923419
26. Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet. 2012;379(9823): 1310–1319. doi: 10.1016/S0140-6736(11)61817-5 22357106
27. Dreischulte T, Donnan P, Grant A, Hapca A, McCowan C, Guthrie B. Safer prescribing—a trial of education, informatics, and financial incentives. N Engl J Med. 2016;374(11): 1053–1064. doi: 10.1056/NEJMsa1508955 26981935
28. Guthrie B, Kavanagh K, Robertson C, Barnett K, Treweek S, Petrie D, et al. Data feedback and behavioural change intervention to improve primary care prescribing safety (EFIPPS): multicentre, three arm, cluster randomised controlled trial. BMJ. 2016;354: i4079. doi: 10.1136/bmj.i4079 27540041
29. Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, et al. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet. 2012;379(9833): 2252–2261. doi: 10.1016/S0140-6736(12)60480-2 22683130
30. McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014;67(3): 267–277. doi: 10.1016/j.jclinepi.2013.08.015 24275499
31. Berwick DM. The science of improvement. JAMA. 2008;299(10): 1182–1184. doi: 10.1001/jama.299.10.1182 18334694
32. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337: a1655. doi: 10.1136/bmj.a1655 18824488
33. Grol R, Dalhuijsen J, Thomas S, Veld C, Rutten G, Mokkink H. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ. 1998;317(7162): 858–861. doi: 10.1136/bmj.317.7162.858 9748183
34. Hallsworth M, Chadborn T, Sallis A, Sanders M, Berry D, Greaves F, et al. Provision of social norm feedback to high prescribers of antibiotics in general practice: a pragmatic national randomised controlled trial. Lancet. 2016;387(10029): 1743–1752. doi: 10.1016/S0140-6736(16)00215-4 26898856
35. Foy R, Leaman B, McCrorie C, Petty D, House A, Bennett M, et al. Prescribed opioids in primary care: cross-sectional and longitudinal analyses of influence of patient and practice characteristics. BMJ Open. 2016;6(5): e010276. doi: 10.1136/bmjopen-2015-010276 27178970
36. Holt TA, Dalton A, Marshall T, Fay M, Qureshi N, Kirkpatrick S, et al. Automated software system to promote anticoagulation and reduce stroke risk: cluster-randomized controlled trial. Stroke. 2017;48(3): 787–790. doi: 10.1161/STROKEAHA.116.015468 28119433
Článek vyšel v časopise
PLOS Medicine
2020 Číslo 2
- Jak a kdy u celiakie začíná reakce na lepek? Možnou odpověď poodkryla čerstvá kanadská studie
- Prof. Jan Škrha: Metformin je bezpečný, ale je třeba jej bezpečně užívat a léčbu kontrolovat
- FDA varuje před selfmonitoringem cukru pomocí chytrých hodinek. Jak je to v Česku?
- Infekce se v Americe po příjezdu Kolumba šířily nesrovnatelně déle, než se traduje
- Ibuprofen jako alternativa antibiotik při léčbě infekcí močových cest
Nejčtenější v tomto čísle
- Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study
- Digitally enabled aged care and neurological rehabilitation to enhance outcomes with Activity and MObility UsiNg Technology (AMOUNT) in Australia: A randomised controlled trial
- The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial
- An evaluation of Chile’s Law of Food Labeling and Advertising on sugar-sweetened beverage purchases from 2015 to 2017: A before-and-after study